contact us to

get started

Contact Sales
.
005-pills

Transparency Talks. Get clarity into state drug price transparency mandates

Rising drug prices and their associated impacts have led many states to propose and pass legislation to increase visibility into drug pricing. More than 20 states have these laws on their books, and now pharmaceutical manufacturers must figure out how to effectively manage and comply with these complex and diverse requirements.

Join Model N and our special guests from Global Pricing Innovations (GPI) and Pfizer for a series of 30-minute webinars, where we’ll talk about the ins and outs of navigating the ever-changing environment of state drug price transparency mandates. We’ll discuss trends, best practices, and innovative approaches for ensuring compliance.

The Importance of Automating Treatment Cost Data

Speaker Image
Rachel Jao
Head of Commercial Strategy Global Pricing Innovations
Speaker Image
Kyle Forcier
Sr. Director, Product Marketing Model N

Tuesday, August 30 at 8 a.m. PST (11 a.m. EST)

As part of their drug price transparency mandates, many states require that pharmaceutical manufacturers submit 30-day wholesale acquisition cost (WAC) information. But calculating and maintaining 30-day or annual WAC data is manually intensive. In our second Transparency Talk, we’ll highlight how you can automate these 30-day calculations to streamline the process of providing cost of treatment data to requesting states.

How Pfizer Conquered the Challenges of Transparency Reporting

Speaker Image
Laura Topal
Senior Director, Strategic Pricing (US) Pfizer
Speaker Image
Jesse Mendelson
VP, COE Model N
Speaker Image
Kyle Forcier
Sr. Director, Product Marketing Model N

Tuesday, September 13 at 8 a.m. PST (11 a.m. EST)

Complying with the vast set of state-specific transparency rules, formats, and timelines, while facilitating complete traceability and standardization, is no easy feat. In our final Transparency Talk, we’ll hear how Pfizer operationalized their state price transparency reporting process with help from Model N State Price Transparency Management. Laura Topal, Senior Director, Strategic Pricing (US) at Pfizer, will share how they’re able to effectively manage legislation rules, make data-driven pricing decisions, and autogenerate reports based on each state’s unique triggering events.

The Truth About Transparency: What’s Happening on the State Level?

Speaker Image
Jesse Mendelsohn
VP, COE Model N
Speaker Image
Kyle Forcier
Sr. Director, Product Marketing Model N

On-Demand

Since each state has its own requirements for what, when, and how to report, getting a handle on these mandates can be tedious and challenging. In the first Transparency Talk, we’ll provide an overview of the current regulatory environment and discuss the associated operational and compliance-related challenges. We’ll also give you a brief look at Model N Price Transparency Management – our innovative, purpose-built solution that streamlines reporting and mitigates risk of non-compliance.

Solution Brief
Solution Brief
Solution Brief
State Price Transparency Management
VIEW Solution Brief
Whitepaper
Whitepaper
Whitepaper
Taking a Lifecycle Approach to Revenue Management
Finding the right partner for your commercialization and maturity journey VIEW Whitepaper
Video
Video
Video
State Price Transparency Management
Model N State Price Transparency Management delivers the right balance of automation, flexibility, and diligence to ensure price transparency reporting is accurate and delivered on time. VIEW Video
.

Start typing and press Enter to search